Venmax Drugs & Pharmaceuticals Limited has submitted its unaudited standalone financial results for Q3FY26 along with its quarterly compliance statement confirming no deviation in preferential issue fund utilization. The company reported total revenue of ₹162.06 lakhs for the quarter ended December 31, 2025, marking a significant turnaround from the previous year.

Q3FY26 Financial Performance

The company demonstrated strong operational recovery with substantial revenue growth and return to profitability. The financial results were approved by the Board of Directors on February 7, 2026, following audit committee review.

Nine Months Performance

For the nine months ended December 31, 2025, the company achieved total revenue of ₹414.93 lakhs compared to ₹50.44 lakhs in the corresponding period of the previous year, representing a growth of over 720%.

Fund Utilization Compliance

Simultaneously, the company filed its quarterly statement confirming no deviation in the utilization of funds raised through its preferential issue. The fund raising exercise was completed on March 20, 2025, with total amount of ₹20.05 crores to be raised.

The proceeds were allocated for working capital (₹10 crores) and general corporate purposes including business acquisition (₹10.05 crores), with ₹3.79 crores and ₹0.19 crores utilized respectively, showing no deviation from stated objectives.

Corporate Governance

Both the financial results and fund utilization statement were reviewed by the Audit Committee and approved by the Board of Directors on February 7, 2026. The statutory auditors PPKG & Co Chartered Accountants conducted a limited review of the financial results and expressed an unmodified conclusion. The company confirmed compliance with Regulation 33 and Regulation 32 of SEBI (LODR) Regulations, 2015, demonstrating strong governance practices and transparent disclosure to stakeholders.

Venmax drugs & pharmaceuticals Limited has completed the allotment of 7,75,000 equity shares through warrant conversion on January 21, 2026. The Board of Directors approved the conversion after three warrant holders exercised their conversion rights, originally allotted warrants on March 20, 2025.

Warrant Conversion Details

The allotment involved conversion of warrants at an issue price of ₹20 per share, comprising face value of ₹10 and premium of ₹10 each. The warrant holders paid the balance exercise price of ₹15 per warrant, representing 75% of the total warrant exercise price, aggregating to ₹1,16,25,000.

Allottee Breakdown

All three warrant holders who exercised conversion rights belong to the non-promoter category. The conversion was executed on a 1:1 basis, with each warrant converting into one equity share.

Impact on Share Capital

Following the allotment, the company's paid-up capital has increased substantially. The new capital structure reflects the successful conversion of a portion of the outstanding warrants issued under the preferential allotment scheme.

Outstanding Warrants

The conversion represents partial utilization of the total warrants issued. Out of the original 1,00,25,000 warrants allotted in March 2025, a significant portion remains available for future conversion by other warrant holders.

The allotment was conducted under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, following preferential allotment norms. The Board meeting for approving the conversion commenced at 4:00 PM and concluded at 5:00 PM on January 21, 2026.